Chapter 1 - An Introduction to the Current Management of Colorectal Cancer in the Era of Personalized Oncology.
Chapter 2 - Colorectal Cancer Genetics: An Overview of the Actionable Building Blocks.
Chapter 3 - The Arrival of Next-Generation Sequencing: An Overview of Current Technologies.
Chapter 4 - Next-Generation Sequencing for Colorectal Cancer Management.Chapter 5 - Gut Microbiota, Next-Generation Sequencing, Immune Checkpoint Inhibitors and Colorectal Cancer: How Hot is the Link?
Chapter 6 - The Revolution of Liquid Biopsy and Single-Cell Sequencing in the Management of Colorectal Cancer.
Chapter 7 - Overview of Cost-Effectiveness and Limitations of Next-Generation Sequencing in Colorectal Cancer.
Khalid El Bairi is the founder of The Cancer Biomarkers Working Group, and he is currently pursuing clinical and translational research in medical oncology. He has published many peer-reviewed articles in the field of predictive and prognostic cancer biomarkers to improve survival outcomes in several WoS and Medline-indexed journals. His research focuses particularly on biomarkers for digestive and gynecological cancers such as ovarian and colorectal malignancies. He is currently a member of the board of various international scientific societies such as the International Gynecologic Cancer Society (IGCS), European Society for Medical Oncology (ESMO), American Society of Clinical Oncology (ASCO), European Society of Gynaecological Oncology (ESGO), and the American Association for Cancer Research (AACR). He is also an editor and reviewer for more than 40 journals including BMC Cancer, PLoS ONE and Frontiers in Oncology and a guest editor for several special issues on gynecological cancers including Seminars in Cancer Biology and Current Drug Targets. He is also highly interested in teaching evidence-based medicine, clinical research methods, and publishing ethics to medical and Ph.D students and was selected for the 70th Lindau Nobel Laureate Meeting as a young scientist.